ASCO Endorses AUA/ASTRO Treatment Guideline Regarding Radiotherapy After Prostatectomy
the Cancer Therapy Advisor take:
The American Society of Clinical Oncology (ASCO) recently released their endorsement of the American Urological Association (AUA) and American Society for Radiation Oncology (ASTRO) practice guideline regarding adjuvant and salvage radiotherapy after prostatectomy.
The ASTRO and AUA Guideline states that the discussion about adjuvant radiotherapy should be held between a patient and their oncologist after the patient displays adverse pathologic findings at prostatectomy (ie, positive surgical margins, seminal vesicle invasion, extraprostatic extension).
The guideline also stated that oncologists should discuss salvage radiotherapy with their patients with local recurrence or PSA after prostatectomy. The guideline recommends that the discussion of radiotherapy includes an outline of the potential adverse events (both long-term and short-term) as well as the potential for benefit.
The guideline indicates that after the discussion occurs, the decision regarding whether or not the oncology team should administer radiotherapy should be made by both the multidisciplinary team and the patient, with the understanding that there is not one equal rate of risk of recurrence or clinically meaningful disease progression for every patient and the risk-benefit ratio is different for each individual.
By endorsing this guideline ASCO is stating that their panel of experts determined that the guideline is thorough, clear, and based on the most scientifically relevant evidence in this area.
ASCO released endorsement of the AUA/ASTRO practice guideline.
Purpose of this study is to endorse the American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO) guideline on adjuvant and salvage radiotherapy after prostatectomy. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines developed by other professional organizations.
The discussion of radiotherapy should include possible short– and long–term adverse effects and potential benefits. The decision to administer radiotherapy should be made by the patient and multidisciplinary treatment team, keeping in mind that not all men are at equal risk of recurrence or clinically meaningful disease progression.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Plastics and Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer